"small cell cancer" trang 10 - tải miễn phí từ tailieunhanh
A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer

A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer
8    67    1
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
9    54    1
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
7    61    1
PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: A diagnostic test study (LACOG 0114)

PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: A diagnostic test study (LACOG 0114)
8    71    1
Prophylactic cranial irradiation in small cell lung cancer: A systematic review and metaanalysis

Prophylactic cranial irradiation in small cell lung cancer: A systematic review and metaanalysis
10    35    1
Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome
9    74    1
Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: A systematic review

Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: A systematic review
5    61    1
Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia

Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia
7    58    1
MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway

MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway
11    32    1
Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage

Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage
11    81    1
EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: A systematic review and metaanalysis

EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: A systematic review and metaanalysis
6    42    1
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
6    36    1
A molecular and staging model predicts survival in patients with resected non-small cell lung cancer

A molecular and staging model predicts survival in patients with resected non-small cell lung cancer
8    39    1
Serum low-density lipoprotein and lowdensity lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)

Serum low-density lipoprotein and lowdensity lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)
9    47    1
A prediction model for lymph node metastases using pathologic features in patients intraoperatively diagnosed as stage I non-small cell lung cancer

A prediction model for lymph node metastases using pathologic features in patients intraoperatively diagnosed as stage I non-small cell lung cancer
8    53    1
Identifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients

Identifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients
8    93    1
The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases

The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases
9    63    1
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A comparative study

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: A comparative study
8    48    1
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
8    59    1
Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors
7    75    1